Allogene Therapeutics Overview

  • Founded
  • 2017
Founded
  • Status
  • Public
  • Employees
  • 265
Employees
  • Stock Symbol
  • ALLO
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $27.50
  • (As of Friday Closing)

Allogene Therapeutics General Information

Description

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Primary Office
  • 210 East Grand Avenue
  • South San Francisco, CA 94080
  • United States
+1 (415) 000-0000

Allogene Therapeutics Timeline

2018201920202021
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Allogene Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.50 $26.94 $24.85 - $55.00 $3.89B 142M 880K -$1.83

Allogene Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 4,190,741 2,750,495 2,703,462 3,603,635
Revenue 38,345 0 0 0
EBITDA (227,710) (251,799) (197,249) (212,553)
Net Income (228,756) (250,221) (184,594) (211,505)
Total Assets 1,179,044 1,227,829 717,802 773,855
Total Debt 51,625 53,783 53,028 34,456
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Allogene Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Allogene Therapeutics‘s full profile, request access.

Request a free trial

Allogene Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Allogene Therapeutics‘s full profile, request access.

Request a free trial

Allogene Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the d
Biotechnology
South San Francisco, CA
265 As of 2020
00000
0.00 0000-00-00
00000000 00000

00000000

t, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
0000000000000
Framingham, MA
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allogene Therapeutics Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Corporation Framingham, MA 0 000.00 000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
0000000 0000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
You’re viewing 5 of 35 competitors. Get the full list »

Allogene Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
David Chang Ph.D Chief Executive Officer, President & Founder
Eric Schmidt Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Alison Moore Ph.D Chief Technology Officer, Technology
Barbra Sasu Ph.D Chief Scientific Officer
Christine Cassiano Chief Communications Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Allogene Therapeutics Board Members (9)

Name Representing Role Since
Arie Belldegrun MD Self Chairman & Founder 000 0000
David Bonderman JD Self Board Member 000 0000
Deborah Messemer Allogene Therapeutics Board Member 000 0000
Franz Humer Ph.D Allogene Therapeutics Board Member 000 0000
John DeYoung Allogene Therapeutics Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Allogene Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allogene Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Allogene Therapeutics‘s full profile, request access.

Request a free trial

Allogene Therapeutics Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 10-Feb-2021 00000 00000 00 0000 Drug Discovery 00000 00000 00.0
00000000 00000000 15-Dec-2020 00000 0000000 Pharmaceuticals 00000 00000 00.0
Notch Therapeutics 01-Nov-2019 Seed Round 00.000 Drug Discovery 00000 00000 00.0
To view Allogene Therapeutics’s complete investments history, request access »